The most common grade ≥3 AEs leading to treatment discontinuation with asciminib included thrombocytopenia (3.2%) and neutropenia (2.6%) and with bosutinib included increased ALT (3.9%), neutropenia (3.9%), and pleural effusion (2.6%) (Supplementary Table S8). Here, GPT is linked to Pleural effusion.